A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.
Risk Adjusted Net Present Value: What is the current valuation of Tenaya Therapeutics’s TN-201
The revenue for TN-201 is expected to reach an annual total of $37 mn by 2038 in the US based off GlobalDatas Expiry Model. The